LAUSR

PURPOSE To determine the risk factors for re-treatment following LASIK in hyperopic eyes. METHODS In this retrospective study, consecutive hyperopic eyes underwent LASIK at the Care Vision Laser Centers, Tel-Aviv, Israel, between January 2000 and October 2014. Patients were divided into two groups according to whether or not they underwent additional refractive surgery (re-treatment). Logistic regression was performed to determine predictors of re-treatment. RESULTS Overall, 1,776 eyes of 888 patients were included, of which 82 (4.6%) needed re-treatment. Eyes that underwent re-treatment were of older age (49.1 ± 7.5 vs 46.9 ± 10.3 years, P = .01), had better preoperative CDVA (1.0 ± 0.14 vs 0.95 ± 0.15 decimal, P = .001), were treated more often with the Allegretto EX200 (Alcon Laboratories, Inc., Fort Worth, TX) as opposed to the EX-500 (90.2% vs 63.7%, P < .001), and were treated with a Moria M2-90 microkeratome (Moria S.A., Antony, France) as opposed to Moria SBK-90 (66.7% vs 36.4%, P < .001). Multiple logistic regresison analysis demonstrated that treatment with Allegretto EX200 (odds ratio: 2.67, P = .04), and Moria M2-90 microkeratome (odds ratio: 2.23, P = .04) and older age (odds ratio: 1.03, P = .03) were significant risk factors for re-treatment. CONCLUSIONS Factors associated with a higher risk of re-treatment following hyperopic LASIK include type of laser, type of microkeratome used, and older age. Identifying such factors may aid in reducing future retreatment rates in hyperopic LASIK. [J Refract Surg. 2018;34(5):316-320.].